Dr. Arlene Sharpe on the Discovery and Further Use of the PD-L1 Pathway

March 1, 2016
Arlene Sharpe, MD, PhD

Sharpe, whose lab aided in the discover of the pathway, says blocking the pathway in order to treat cancers is important because it allows T cells to work better.

Arlene Sharpe, MD, PhD, immunology faculty member, Harvard Medical School, discusses the discovery of the PD-L1 pathway and the importance of the pathway in inhibiting anti-tumor immunity. Sharpe, whose lab aided in the discover of the pathway, says blocking the pathway in order to treat cancers is important because it allows T cells to work better.

Sharpe adds that the pathway was initially tested in both melanoma and lung cancer, which proved the pathway's usefulness in essentially all cancer types.